$0.06
(Market cap
$37 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
45.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-25.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
14,979,502
10 Years Aggregate
CFO
$-221.58 Mln
EBITDA
$-247.38 Mln
Net Profit
$155.94 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Dare Bioscience Inc (DARE)
| 23.6 | -16.9 | 44.6 | -17.4 | -42.2 | -31.5 | -37.8 |
|
BSE Sensex
| -11.2 | -4.2 | -9.2 | -7.4 | 6.8 | 8.7 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Dare Bioscience Inc (DARE)
| -38.1 | -15.7 | -62.8 | -58.5 | 49.3 | 63.4 | 15.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Dare Bioscience Inc (DARE)
|
2.4 | 36.7 | 1.2 | -12.0 | -775.2 | -669.2 | -- | 45.8 |
| 74.8 | 10,307.9 | 622.0 | -300.9 | -30.1 | -62 | -- | 17.6 | |
| 242.4 | 14,777.7 | 867.5 | 506.6 | -2.8 | -- | 27.2 | 25.9 | |
| 78.2 | 10,379.7 | 105.8 | -829.6 | -715.0 | -- | -- | 60.5 | |
| 49.4 | 12,233.5 | 2,375.5 | 833.4 | 40.8 | 40.7 | 16.1 | 6.5 | |
| 119.4 | 13,020.0 | 1,080.2 | -433.2 | -39.8 | -- | -- | 60.9 | |
| 300.0 | 8,785.0 | 417.3 | 225.0 | 42.8 | 18.6 | 39.9 | 6.8 | |
| 507.6 | 11,800.4 | 1,132.5 | -309.4 | -25.5 | -52.9 | -- | 21.7 | |
| 422.3 | 11,992.5 | 2,678.3 | 460.4 | 21.1 | 103.2 | 26.4 | 20.0 | |
| 342.0 | 8,938.2 | 0.0 | -326.5 | -- | -37.2 | -- | 6.3 |
Shareholding Pattern
View DetailsAbout Dare Bioscience Inc (DARE)
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the... treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1 and DARE-PTB1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB2 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California. Address: 3655 Nobel Drive, San Diego, CA, United States, 92122 Read more
-
CEO, President, Principal Financial Officer, Secretary & Director
Ms. Sabrina Martucci Johnson
-
CEO, President, Principal Financial Officer, Secretary & Director
Ms. Sabrina Martucci Johnson
-
Headquarters
San Diego, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Dare Bioscience Inc (DARE)
What is the current share price of Dare Bioscience Inc (DARE) Today?
The share price of Dare Bioscience Inc (DARE) is $2.39 (NASDAQ) as of 21-May-2026 11:33 EDT. Dare Bioscience Inc (DARE) has given a return of -42.2% in the last 3 years.
What is the current PB & PE ratio of Dare Bioscience Inc (DARE)?
Since, TTM earnings of Dare Bioscience Inc (DARE) is negative, P/E ratio is not available.
The P/B ratio of Dare Bioscience Inc (DARE) is 45.83 times as on 20-May-2026, a 963 premium to its peers’ median range of 4.31 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-1.58
|
7.47
|
|
2024
|
-6.16
|
-4.15
|
|
2023
|
-0.07
|
-0.43
|
|
2022
|
0.01
|
0.52
|
|
2021
|
-0.26
|
0.26
|
What is the 52 Week High and Low of Dare Bioscience Inc (DARE)?
The 52-week high and low of Dare Bioscience Inc (DARE) are Rs 9.19 and Rs 1.27 as of 21-May-2026.
What is the market cap of Dare Bioscience Inc (DARE)?
Dare Bioscience Inc (DARE) has a market capitalisation of $ 37 Mln as on 20-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Dare Bioscience Inc (DARE)?
Before investing in Dare Bioscience Inc (DARE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.